Large dose of pamidronate disodium in treatment for patients with painful bone metastases of prostate cancer
10.3760/cma.j.issn.1671-7368.2010.08.009
- VernacularTitle:大剂量帕米膦酸二钠治疗前列腺癌骨转移疼痛的临床观察
- Author:
Bo LUO
;
Lijiang SUN
;
Peng LIU
;
Jianbo HAO
;
Baolian SONG
;
Jinfeng ZHANG
- Publication Type:Journal Article
- Keywords:
Neoplasm metastasis;
Bone;
Bisphosphonates;
Prostatic neoplasms;
Pain
- From:
Chinese Journal of General Practitioners
2010;09(8):536-539
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study efficacy and safety of large dose of pamidronate disodium in treatment for patients with painful bone metastasis of prostate cancer. Methods A total of 100 patients with painful bone metastasis of prostate cancer were randomized into large dose group and conventional dose group, with 50 cases each. Pamidronate disodium was administered by intravenous infusion, 90 mg on the first day and 60 mg on the second day for large dose group, and 60 mg on the first day and 30 mg on the second day for conventional dose group, respectively, every 4 weeks for two courses. Changes of pain,mobility, quality of life and adverse effect in patients before and after treatment were observed. Results After treatment, pain was relieved in 43 of 50 patients ( 86% ) in large dose group, significantly more than that in conventional dose group (21/50, 42% ) (χ2 = 22.79, P ＜ 0. 01 ). Both mobility and quality of life were improved in 39 and 33 patients ( 87% and 66% ), respectively in large dose group and 21 and 18 (46% and 36% ), respectively in conventional dose group (χ2 = 17.04 and 9. 00, P ＜0. 01 ). No severe adverse effect in both groups was observed. Conclusions Pain in patients with bone metastasis of prostate cancer can be significantly relieved with large dose of pamidronate disodium, as well as their quality of life improved.
